SRPT
Sarepta Therapeutics Inc
18.70$
+1.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
Sarepta Therapeutics Inc (SRPT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -205 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.6 | -3.0 | -6.7 | -7.6 | -9.1 | -13 | -20 | -17 | -24 | -15 | -21 | -25 | -12 | -8.8 | -15 | -24 | -30 | -65 | -129 | -149 | -246 | -232 | -389 | -456 | 107 | -443 | -325 | -501 | -206 | -205 | |
| 0.5 | 0.5 | 0.2 | 0.3 | 0.4 | 0.6 | 1.3 | 1.5 | 1.9 | 2.0 | 2.1 | 2.0 | 1.5 | 1.4 | 1.5 | 1.3 | 1.5 | 1.3 | 3.7 | 5.2 | 5.6 | 8.1 | 12 | 25 | 27 | 38 | 42 | 44 | 38 | 45 | |
| – | – | – | – | – | 0.1 | 0.5 | 0.5 | 0.4 | 0.4 | 0.5 | 0.3 | 0.2 | 2.4 | 3.2 | 3.1 | 3.1 | 11 | 20 | 32 | 30 | 30 | 50 | 79 | 108 | 114 | 233 | 183 | 184 | 123 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 3.2 | 3.1 | 34 | 23 | 33 | 31 | -91 | 77 | 274 | 178 | 32 | 376 | – | – | – | |
| 0.1 | 0.1 | 0.2 | 0.4 | -0.3 | 0.8 | 2.6 | -1.1 | -1.4 | -0.4 | 1.4 | -0.4 | -2.8 | 2.9 | -0.4 | 6.9 | -5.3 | 12 | -22 | 32 | -16 | -97 | -108 | -67 | 554 | -98 | -39 | -481 | -717 | 78 | |
| 0.1 | 0.3 | 2.3 | 0.2 | 0.8 | 4.2 | 2.8 | 1.6 | 1.1 | 1.5 | 1.5 | 2.1 | 1.2 | 2.0 | 2.0 | 2.3 | 1.1 | 3.8 | 27 | 4.8 | 6.9 | 21 | 64 | 60 | 82 | 38 | 32 | 87 | 147 | 102 | |
| 0.1 | -0.5 | -2.6 | -0.5 | -1.1 | -13 | -2.4 | -15 | 21 | -11 | – | 11 | -1.2 | -1.9 | -2.0 | -2.3 | -1.1 | -12 | -159 | 8.4 | -90 | -179 | -370 | 287 | -122 | 495 | -1,047 | -166 | 756 | 70 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | 241 | 286 | – | – | – | – | – | |
| – | -0.3 | – | – | – | 0.1 | 0.1 | 0.1 | – | – | – | 0.8 | 0.2 | – | – | 32 | 179 | 146 | 104 | 131 | 365 | 354 | 564 | -4.3 | -4.8 | -7.8 | – | 0.0 | 0.0 | -25 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -0.1 | -0.1 | -0.1 | -0.1 | 17 | -7.6 | 570 | -3.5 | 245 | 291 | 304 | 304 | 0.0 | -0.1 | -163 | |
| 3.9 | 18 | 0.2 | 8.2 | 27 | 11 | 22 | 35 | 7.1 | 44 | 8.2 | 19 | 0.0 | 48 | 2.5 | 32 | 179 | 146 | 104 | 148 | 378 | 888 | 530 | 643 | 682 | 562 | 233 | 125 | 125 | -168 | |
| 3.9 | 18 | 0.2 | 0.2 | 17 | -15 | -0.7 | 2.1 | 4.1 | 18 | -14 | 4.6 | -14 | 37 | -15 | 6.3 | 148 | 69 | -183 | 6.8 | 42 | 477 | -229 | 473 | 668 | 614 | -1,140 | -542 | 675 | -304 | |
| -1.7 | -3.3 | -9.0 | -7.8 | -9.9 | -17 | -23 | -19 | -25 | -16 | -22 | -27 | -14 | -11 | -17 | -26 | -31 | -68 | -155 | -154 | -253 | -253 | -453 | -516 | 25 | -482 | -358 | -588 | -353 | -307 |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.